Controversies in the use of insulin analogues

Bibliography

• Hagedorn HC, Norman Jensen B, Krarup NB. Wodstrup I. Protamine insulinate. JAMA 1936;106:177-80
   Google Scholar
• Scott DA, Fisher AM. Crystalline insulin. Biochem J 1935;29:1048-54
   PubMedGoogle Scholar
• Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Hosp (Copenh) 1946;1:60-73
   Google Scholar
• Brange J. The new era of biotech insulin analogues. Diabetologia 1997;40:S48-53
   PubMed Web of Science ®Google Scholar
• Dideriksen LH, Jorgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 1992;41:143A
   Google Scholar
• Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54
   PubMed Web of Science ®Google Scholar
• Brems DN, Alter LA, Beckage MJ, Altering the association properties of insulin by amino acid replacement. Protein Eng 1992;5:527-33
   PubMedGoogle Scholar
• Barlocco D. Insulin Glulisine. Aventis pharma. Curr Opin Investig Drugs 2003;4:1240-4
   PubMedGoogle Scholar
• Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000;59:253-60
   PubMed Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Pharmacokinetics and pharmacodynamics of subcutaneous injecting of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Havelund S, Jonassen I, Albumin binding of insulins acylated with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725-31
   PubMed Web of Science ®Google Scholar
• Hamilton-Wessler M, Ader M, Dea M, Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999;42:1254-63
   PubMed Web of Science ®Google Scholar
• Butler PC. Insulin glargine controversy: a tribute to the editorial team at diabetologia. Diabetes 2009;58:2427-8
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009;374:511-13
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, Insulin glargine use and short term incidence of malignancies-a population based follow up study in Sweden. Diabetologia 2009;52:1745-54
   PubMed Web of Science ®Google Scholar
• Colhoun HM. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-65
   PubMed Web of Science ®Google Scholar
• Rosemstock J, Fonseca V, McGill JB, Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009:52:1971-73
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Balzi D, Doses of insulin and its analogues and cancer occurrence in insulin treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
   PubMed Web of Science ®Google Scholar
• Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-506
   PubMed Web of Science ®Google Scholar
• Forjanic-Klapproth J, Home PD. Progression of retinopathy with insulin glargine or NPH-a multi-trial analysis. Diabetologia 2001;44 (Suppl):1103
   Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6
   PubMed Web of Science ®Google Scholar
• Neumann E, Frei E, Funk D, Native albumin for targeted drug delivery. Exp Opin Drug Deliv 2010;7:915-25
   PubMed Web of Science ®Google Scholar
• Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin determir: a meta analysis. Diabetologia 2009;52:2507-12
   PubMed Web of Science ®Google Scholar
• Singh SR, Ahmad F, Lal A, Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta analysis. Can Med Assoc J 2009;180:385-97
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Schaffer L, Sorensen A, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005
   PubMed Web of Science ®Google Scholar
• Laron Z. Insulin-like growth factor-1: a growth hormone. Mol Pathol 2001;54:311-16
   PubMedGoogle Scholar
• Laron Z. IGF-1 and insulin as growth hormones. In: LeRoith D, Goode J, Bock G, editors, Biology of IGF-1: its interaction with insulin in health and malignant states. John Wiley & Sons Ltd, Chichester, UK; 2004. p. 58-63
   Google Scholar
• Bahr MT, Kolter G, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997;320:259-65
   PubMed Web of Science ®Google Scholar
• Eckardt K, May C, Koenen M, Eckel J. IGF-I receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007;50:2534-43
   PubMed Web of Science ®Google Scholar
• Sciacca L, Cassarino MF, Genua M, Insulin analogues differently activate insulin rceptor isoforms and post-receptor signalling. Diabetologia 2010;53:1743-53
   PubMed Web of Science ®Google Scholar
• Weinstein D, Simon M, Yehezkel E, Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-9
   PubMed Web of Science ®Google Scholar
• Staiger K, Hennige AM, Staiger H, Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007;39:65-7
   PubMed Web of Science ®Google Scholar
• Yehezkel E, Weinstein D, Simon M, Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 2010;53:2667-75
   PubMed Web of Science ®Google Scholar
• Shukla A, Grisouard J, Ehemann V, Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009;16:429-41
   PubMed Web of Science ®Google Scholar
• Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010;116:73-8
   PubMedGoogle Scholar
• Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38-44
   PubMedGoogle Scholar
• Shukla A, Enzmann H, Mayer D. Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. Arch Physiol Biochem 2009;115:119-26
   PubMedGoogle Scholar
• Stammberger I, Bube A, Durchfeld-Meyer B, Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002;21:171-9
   PubMed Web of Science ®Google Scholar
• Holleman F, Gale EAM. Nice insulins, pity about the evidence. Diabetologia 2007;50:1783-90
   PubMed Web of Science ®Google Scholar
• Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer-An unsubstantiated allegation. Diabetes Technol Therap 2009;11:473-6
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708
   PubMed Web of Science ®Google Scholar
• Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006;8:611-20
   PubMed Web of Science ®Google Scholar
• Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause celebre? Int J Clin Pract 2010;64:628-36
   PubMed Web of Science ®Google Scholar
• Gale EAM. Insulin glargine and cancer: another side of the story? Lancet 2009;374:521
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Diabetes and cancer-a consensus report. Diabetes Care 2010;33:1674-83
   PubMed Web of Science ®Google Scholar
• Banting FG, Best CH, Collip JB, Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-6
   PubMedGoogle Scholar
• Whittingham JL, Havelund S, Jonassen I. Crystal structure of prolonged-acting insulin with albumin-binding properties. Biochemistry 1997;36:2826-31
   PubMed Web of Science ®Google Scholar